Community-acquired pneumonia patients treated with high dose oral levofloxacin tablets: a clinical analysis of 53 mild and moderate cases
Abstract
OBJECTIVE To investigate the effects and safety of high dose oral levofloxacin tablets on mild and moderate community-acquired pneumonia(CAP).METHODS A study was conducted in 53 mild and middle CAP patients and the course of treatment was 7 to 14 days.RESULTS High dose oral levofloxacin tablets were effective in 86.8% of all CAP patients and pathogens were eradicated in 86.9% patients.The adverse effects were seen in 9.4% patients and mild complaint in gastrointestinal tract was common.CONCLUSIONS High dose oral levofloxacin tablets are effective and safe in the treatment of mild and moderate CAP patients.The cost and adverse effects are lower compared with normal treatment.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.